Products for Research Use Only

Antitumor agent-170

CAT: 0804-HY-162644Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-162644Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC50 of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a Ki of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics[1].
CAS Number
9007-83-4
UNSPSC
12352005
Target
PARP; PD-1/PD-L1
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/antitumor-agent-170.html
Smiles
CC1=C(C=CC=C1C2=CC=CC=C2)COC3=C(C=C(C(OCC4=CN=CC=C4)=C3)CN5CCCC[C@H]5C(NCCOCCOCCNC(C6=CN=C(N=C6)N7CCN(CC7)C(CCOC[C@H](C)NC8=C(C(NN=C8)=O)C(F)(F)F)=O)=O)=O)Cl
Molecular Formula
C59H69ClF3N11O9
Molecular Weight
1168.70
References & Citations
[1]Gao Y, et al., Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment. J Med Chem. 2024 Jun 24.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PARP7